12:00 AM
 | 
Sep 07, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ivabradine: Phase III data

A subgroup analysis of 1,507 patients with angina in the double-blind, international Phase III BEAUTIFUL trial showed that Procoralan ivabradine reduced the composite of cardiovascular death, MI and heart failure by 24% vs. placebo (p=0.048). Procoralan also reduced hospitalization for fatal or...

Read the full 198 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >